1 December 2021
Today we remember and support #WorldAIDSDay. Medical research has seen amazing advances and milestones over the past few decades. Here at IRBM, we are proud to have played a major role in the discovery of Raltegravir (Isentress) while part of Merck & Co, for the treatment of #HIV-1 infection in combination with other antiretroviral agents.
IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
28 May 2020
Pomezia, Italy - Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19.